Insulin and semaglutide are both injectable diabetes medicines, but they work through completely different mechanisms — and, notably, have opposite effects on weight. Insulin is a replacement hormone that lowers blood sugar directly; semaglutide is a GLP-1 receptor agonist that improves the body's own glucose response and curbs appetite. Both are FDA-approved.
At a glance
| Insulin | Semaglutide | |
|---|---|---|
| Class | Hormone (glucose-lowering) | GLP-1 receptor agonist |
| Brand names | Many (Humalog, Lantus, etc.) | Ozempic, Wegovy, Rybelsus |
| FDA status | Approved | Approved |
| How it lowers glucose | Directly drives cellular glucose uptake | Glucose-dependent insulin release; slows gastric emptying |
| Effect on weight | Often weight gain | Weight loss |
| Hypoglycemia risk | Higher | Low (glucose-dependent action) |
The bottom line
Bottom line: Insulin is essential, life-saving replacement therapy — especially in type 1 diabetes — but it can cause weight gain and low blood sugar. Semaglutide works further upstream, improving glucose control while reducing appetite and weight, with low hypoglycemia risk. They are not interchangeable: many people with diabetes use one, the other, or both, as a clinician decides.
Frequently asked questions
Is semaglutide a replacement for insulin?
Not generally. Insulin directly replaces or supplements the body's glucose-lowering hormone and is essential in type 1 diabetes, while semaglutide improves the body's own insulin response and appetite. Some people use both; it is a clinical decision.
Why does insulin cause weight gain but semaglutide cause weight loss?
Insulin promotes glucose storage and can increase appetite, often leading to weight gain, whereas semaglutide reduces appetite and slows gastric emptying, typically producing weight loss.
Which has a higher risk of low blood sugar?
Insulin carries a higher hypoglycemia risk because it lowers glucose directly. Semaglutide acts in a glucose-dependent way, so on its own it has a low risk of hypoglycemia.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Galdón Sanz-Pastor A, Justel Enríquez A, Sánchez Bao A, et al. Current barriers to initiating insulin therapy in individuals with type 2 diabetes. Front Endocrinol (Lausanne). 2024. Peer-reviewed study
- Bargain D, Campinos C. [Closed-loop insulin therapy in type 1 diabetes after age 60]. Soins. 2023. Peer-reviewed study
- Herman ME, O'Keefe JH, Bell DSH, et al. Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. Prog Cardiovasc Dis. 2017. Peer-reviewed study
- Aoki TT, Grecu EO, Arcangeli MA, et al. Chronic intermittent intravenous insulin therapy: a new frontier in diabetes therapy. Diabetes Technol Ther. 2001. Peer-reviewed study
- Norton L, Shannon C, Gastaldelli A, et al. Insulin: The master regulator of glucose metabolism. Metabolism. 2022. Peer-reviewed study
- Tokarz VL, MacDonald PE, Klip A. The cell biology of systemic insulin function. J Cell Biol. 2018. Peer-reviewed study
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. Peer-reviewed study
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. Peer-reviewed study
- Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023. Peer-reviewed study
- Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. Peer-reviewed study
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. Peer-reviewed study
- Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022. Peer-reviewed study